Related Experiment Video

Updated: Aug 8, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

Spironolactone in the long-term management of patients with congestive heart failure

A G Smith

    Current Medical Research and Opinion
    |January 1, 1980
    PubMed

    Insights

    Spironolactone (100 mg daily) effectively treated congestive heart failure by reducing edema and improving body weight. Most patients tolerated the treatment well over 48 weeks.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Congestive heart failure (CHF) poses a significant clinical challenge.
    • Diuretic therapy is a cornerstone in managing CHF symptoms.

    Purpose of the Study:

    • To evaluate the therapeutic efficacy of spironolactone in patients with congestive heart failure.
    • To assess the safety and tolerability of spironolactone in a general practice setting.

    Main Methods:

    • A multi-centre study involving 115 patients with congestive heart failure.
    • Patients received 100 mg of spironolactone once daily for 48 weeks.
    • Clinical and hematological assessments were conducted at baseline and regular intervals.

    Main Results:

    • Spironolactone treatment led to a decrease in body weight.
    • The incidence of pitting and pulmonary edema was reduced.
    • Plasma sodium levels decreased, while plasma potassium levels increased to normal ranges.
    • 79% of patients experienced no side-effects during the 48-week treatment period.

    Conclusions:

    • Spironolactone (100 mg daily) demonstrates therapeutic efficacy in managing congestive heart failure.
    • The drug is well-tolerated, with a low incidence of side-effects in this patient cohort.
    • Spironolactone offers a viable treatment option for congestive heart failure in general practice.

    More Related Videos

    Implantation of Total Artificial Heart in Congenital Heart Disease07:27

    Implantation of Total Artificial Heart in Congenital Heart Disease

    Published on: July 18, 2014

    Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction05:26

    Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

    Published on: May 28, 2019

    Related Concept Videos

    Heart Failure Drugs: Inotropic Agents01:26

    Heart Failure Drugs: Inotropic Agents

    Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
    Heart Failure Drugs: Diuretics01:22

    Heart Failure Drugs: Diuretics

    Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    Heart Failure VI: Adjunct Therapies01:22

    Heart Failure VI: Adjunct Therapies

    Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.